BiPar Sciences Overview
- Founded
-
2002
- Status
-
Acquired/Merged
- Employees
-
20
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$539M
BiPar Sciences General Information
Description
Developer of tumor-selective drugs designed to target multiple cancer types including therapy-resistant and difficult-to-treat cancers. The company offers a poly ribose polymerase inhibitor for metastatic triple-negative breast cancer, ovarian cancer, and other malignancies, a follow-on inhibitor candidate for pancreatic cancer, and an iodothyronine program with anti-tubulin properties, thereby enabling healthcare providers to enhance the anti-tumor effects of chemotherapy.
Contact Information
Primary Office
- 400 Oyster Point Boulevard
- Suite 200
- South San Francisco, CA 94080
- United States
+1 (650) 000-0000
BiPar Sciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 15-Apr-2009 | $539M | 0000 | 00000 | Completed | Generating Revenue |
| 5. Later Stage VC (Series C) | 12-Jan-2009 | 0000 | 0000 | Completed | Generating Revenue | |
| 4. Later Stage VC (Series B1) | 30-Dec-2008 | 000 | 0000 | 000.00 | Completed | Generating Revenue |
| 3. Later Stage VC (Series B) | 26-Feb-2007 | 0000 | 0000 | 0000 | Completed | Generating Revenue |
| 2. Debt - General | 14-Jun-2006 | $5M | $18M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 20-Dec-2004 | $13M | $13M | 000.00 | Completed | Startup |
BiPar Sciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B1 | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 0.000 |
| Series B | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A | 29,893,629 | $0.001000 | $0.03 | $0.44 | $0.44 | 1x | $0.44 | 21.71% |
BiPar Sciences Patents
BiPar Sciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20120245117-A1 | Methods of treating squamous cell lung cancer with 4-iodo-3-nitrobenzamide in combination with gemcitabine and carboplatin | Inactive | 04-Mar-2011 | 0000000000 | |
| AU-2011282223-A1 | Methods of treating breast cancer using 4-iodo-3-nitrobenzamide in combination with anti-tumor agents | Inactive | 19-Jul-2010 | 00000000000 | |
| CA-2805774-A1 | Methods of treating breast cancer using 4-iodo-3-nitrobenzamide in combination with anti-tumor agents | Inactive | 19-Jul-2010 | 00000000000 | |
| EP-2595618-A1 | Methods of treating breast cancer using 4-iodo-3-nitrobenzamide in combination with anti-tumor agents | Inactive | 19-Jul-2010 | 00000000000 | |
| EP-2595619-A1 | Methods of treating metastatic breast cancer with 4-iodo-3-nitrobenzamide and irinotecan | Inactive | 19-Jul-2010 | A61K31/4745 |
BiPar Sciences Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
BiPar Sciences Former Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Asset Management Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Canaan Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Cercano Management | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Domain Associates | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Lighthouse Capital Partners | Venture Capital | Minority | 000 0000 | 000000 0 |